miR-21 may acts as an oncomir by targeting RECK, a matrix metalloproteinase regulator, in prostate cancer
BMC Urology, 05/30/2012
Clinical Article
Reis ST et al. – The authors' results demonstrate RECK as a target of miR–21. They believe that miR–21 may be important in prostate cancer progression through its regulation of RECK, a known regulator of tumor cell invasion.



